68_CD Notes_NNS to_TO Group_NNP financial_JJ statements_NNS 31_CD DECEMBER_NNP 2003_CD 29_CD RELATED_VBN PARTY_NN TRANSACTIONS_NNS Under_IN the_DT provisions_NNS of_IN FRS8_CD ,_, Related_NNP Party_NNP Disclosures_NNS ,_, it_PRP is_VBZ not_RB necessary_JJ to_TO disclose_VB related_JJ party_NN transactions_NNS between_IN the_DT Company_NN ,_, Acambis_NNP Research_NNP Limited_NNP ,_, Acambis_NNP Inc._NNP ._.
Smallpox_NNP Biosecurity_NNP Limited_NNP and_CC Berna_NNP Products_NNPS Corporation_NNP because_IN they_PRP are_VBP eliminated_VBN on_IN preparation_NN of_IN the_DT Groups_NNS financial_JJ statements_NNS ._.
As_IN described_VBN in_IN note_NN 21_CD ,_, the_DT Group_NNP has_VBZ an_DT interest_NN in_IN the_DT Joint_NNP Venture_NNP ._.
Since_IN May_NNP 1999_CD ,_, Acambis_NNP has_VBZ performed_VBN a_DT pre-agreed_JJ work_NN program_NN on_IN behalf_NN of_IN the_DT Joint_NNP Venture_NNP ._.
Costs_NNS incurred_VBN by_IN the_DT Group_NNP on_IN behalf_NN of_IN the_DT Joint_NNP Venture_NNP and_CC corresponding_JJ turnover_NN received_VBN from_IN the_DT Joint_NNP Venture_NNP have_VBP been_VBN included_VBN in_IN the_DT Groups_NNS financial_JJ statements_NNS ._.
For_IN the_DT year_NN ended_VBD 31_CD December_NNP 2003_CD ,_, the_DT Group_NNP has_VBZ included_VBN turnover_NN of_IN 0.3_CD m_NN 2002_CD 0.3_CD m_NN in_IN respect_NN of_IN costs_NNS incurred_VBN in_IN performing_VBG services_NNS for_IN the_DT Joint_NNP Venture_NNP and_CC a_DT loss_NN of_IN 0.1_CD m_NN 2002_CD 0.2_CD m_NN within_IN its_PRP$ Group_NNP financial_JJ statements_NNS ._.
At_IN 31_CD December_NNP 2003_CD ,_, the_DT amounts_NNS the_DT Group_NNP owed_VBD to_TO the_DT Joint_NNP Venture_NNP amounted_VBD to_TO nil_VB 2002_CD nil_NN ._.
Amounts_NNS owed_VBN by_IN the_DT Joint_NNP Venture_NNP to_TO the_DT Group_NNP at_IN 31_CD December_NNP 2003_CD were_VBD nil_JJ 2002_CD nil_NN ._.
In_IN 2002_CD ,_, the_DT Group_NNP took_VBD the_DT view_NN that_IN ,_, taking_VBG into_IN account_NN the_DT increase_NN in_IN its_PRP$ shareholding_NN in_IN Acambis_NNP and_CC the_DT presence_NN of_IN a_DT representative_NN from_IN Baxter_NNP on_IN the_DT Board_NNP ,_, Baxters_NNP influence_NN on_IN Acambis_NNP was_VBD significant_JJ ,_, and_CC therefore_RB Baxter_NNP was_VBD a_DT related_JJ party_NN for_IN the_DT full_JJ year_NN ._.
The_DT Groups_NNS long-term_JJ lease-finance_NN facility_NN with_IN Baxter_NNP is_VBZ described_VBN within_IN Financial_NNP liabilities_NNS in_IN note_NN 22_CD ._.
The_DT Group_NNP made_VBD sales_NNS to_TO Baxter_NNP of_IN 14.1_CD m_NN in_IN the_DT year_NN 2002_CD 0.7_CD m_NN of_IN which_WDT 1.1_CD m_NN 2002_CD 0.7_CD m_NN was_VBD not_RB received_VBN at_IN the_DT year-end_NN ,_, and_CC made_VBD purchases_NNS of_IN goods_NNS and_CC services_NNS from_IN Baxter_NNP of_IN 50.4_CD m_NN 2002_CD 45.7_CD m_NN of_IN which_WDT 9.4_CD m_NN 2002_CD 42.7_CD m_NN was_VBD unpaid_JJ at_IN the_DT year-end_NN ._.
There_EX were_VBD no_DT transactions_NNS between_IN the_DT Company_NN and_CC BPC_NNP prior_RB to_TO its_PRP$ acquisition_NN ._.
30_CD POST_NN BALANCE_NN SHEET_NN EVENTS_NNS In_IN January_NNP 2004_CD ,_, Acambis_NNP announced_VBD the_DT outcome_NN of_IN a_DT project_NN prioritisation_NN review_NN ._.
As_IN a_DT result_NN ,_, an_DT operational_JJ review_NN was_VBD also_RB completed_VBN and_CC Acambis_NNP decided_VBD to_TO consolidate_VB its_PRP$ research_NN activities_NNS at_IN its_PRP$ facility_NN in_IN Cambridge_NNP ,_, Massachusetts_NNP ._.
The_DT research_NN operation_NN in_IN Cambridge_NNP ,_, UK_NNP will_MD close_VB during_IN 2004_CD ._.
However_RB ,_, Acambis_NNP is_VBZ retaining_VBG clinical_JJ and_CC regulatory_JJ functions_NNS in_IN Cambridge_NNP ,_, UK_NNP ,_, as_RB well_RB as_IN various_JJ head_NN office_NN functions_NNS and_CC sales_NNS ,_, marketing_NN and_CC business_NN development_NN ._.
Once_RB the_DT operational_JJ review_NN is_VBZ fully_RB implemented_VBN during_IN 2004_CD ,_, Acambis_NNP headcount_NN is_VBZ expected_VBN to_TO reduce_VB by_IN around_RB 40_CD to_TO around_IN 280_CD worldwide_NN ._.
